- Home
- CHWY vs BMRN Comparison
CHWY vs BMRN Comparison
Compare CHWY & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CHWY | BMRN |
|---|---|---|
| Founded | 2010 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.0B | 10.0B |
| IPO Year | 2019 | 1999 |
Fundamental Metrics
Financial Performance| Metric | CHWY | BMRN |
|---|---|---|
| Price | $25.11 | $58.53 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 23 | 17 |
| Target Price | $44.82 | ★ $87.24 |
| AVG Volume (30 Days) | ★ 7.4M | 1.9M |
| Earning Date | 01-01-0001 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 911.11 | N/A |
| EPS | 0.43 | ★ 1.80 |
| Revenue | ★ $11,861,335,000.00 | $1,313,646,000.00 |
| Revenue This Year | $8.37 | $13.34 |
| Revenue Next Year | $8.28 | $11.42 |
| P/E Ratio | $59.16 | ★ $32.51 |
| Revenue Growth | 6.40 | ★ 17.62 |
| 52 Week Low | $23.06 | $50.76 |
| 52 Week High | $48.62 | $73.18 |
Technical Indicators
Market Signals| Indicator | CHWY | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 42.31 | 42.57 |
| Support Level | $23.06 | $56.08 |
| Resistance Level | $34.72 | $60.52 |
| Average True Range (ATR) | 1.18 | 2.25 |
| MACD | 0.09 | -0.41 |
| Stochastic Oscillator | 20.51 | 1.80 |
Price Performance
Historical ComparisonAbout CHWY Chewy Inc.
Chewy is the largest e-commerce petcare retailer in the US, generating $11.9 billion in fiscal 2024 sales across pet food, treats, hard goods, and pharmacy categories. The firm was founded in 2011, acquired by PetSmart in 2017, and tapped public markets as a stand-alone company in 2019 after spending time developing under the aegis of the pet superstore chain. The firm generates sales from pet food, treats, over-the-counter medications, medical prescription fulfillment, and hard goods like crates, leashes, and bowls.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.